QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
Log in
NASDAQ:RUBY

Rubius Therapeutics Earnings Date, Estimates & History

$5.06
+0.06 (+1.20 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.82
Now: $5.06
$5.12
50-Day Range
$4.81
MA: $5.04
$5.68
52-Week Range
$3.35
Now: $5.06
$14.44
Volume332,217 shs
Average Volume323,582 shs
Market Capitalization$408.68 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09

Earnings

Rubius Therapeutics (NASDAQ:RUBY) Earnings Information

Rubius Therapeutics last announced its earnings results on August 10th, 2020. The reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.03. Rubius Therapeutics has generated ($2.08) earnings per share over the last year. Rubius Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 12th, 2020 based off prior year's report dates.

Rubius Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Rubius Therapeutics (NASDAQ:RUBY) Earnings Estimates

2020 EPS Consensus Estimate: ($2.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20201($0.51)($0.51)($0.51)
Q2 20202($0.55)($0.53)($0.54)
Q3 20202($0.55)($0.53)($0.54)
Q4 20202($0.57)($0.51)($0.54)

Rubius Therapeutics (NASDAQ RUBY) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
11/12/2020
(Estimated)
       
8/10/20206/30/2020($0.50)($0.47)($0.47)N/A
5/11/20203/31/2020($0.56)($0.60)($0.60)Transcript
3/12/202012/31/2019($0.60)($0.56)($0.56)Transcript
11/14/2019Q3($0.53)($0.59)($0.59)N/A
8/13/2019Q2 2019($0.46)($0.50)($0.50)N/A
5/15/20193/31/2019($0.38)($0.42)($0.42)N/A
3/28/201912/31/2018($0.42)($0.35)($0.35)N/A
11/13/2018Q3 2018($0.36)($0.42)($0.42)N/A
8/31/2018Q2 2018($0.60)($3.33)($3.33)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.